Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eagle Pharmaceuticals
(NQ:
EGRX
)
4.370
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eagle Pharmaceuticals
< Previous
1
2
3
4
Next >
EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Eagle Pharmaceuticals, Inc. on Behalf of Eagle Pharmaceuticals Stockholders and Encourages Investors to Contact the Firm
December 01, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Lowey Dannenberg, P.C. is Investigating Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) for Potential Violations of the Federal Securities Laws
December 01, 2023
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
November 30, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)
November 30, 2023
From
Kirby McInerney LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
November 30, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – EGRX
November 30, 2023
From
Rosen Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors
November 29, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
February 01, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
January 31, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
January 18, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
January 05, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
December 29, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
December 20, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
December 15, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
November 22, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
November 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
October 28, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
September 07, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at September Healthcare Conferences
September 01, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
August 25, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
July 28, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
June 24, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
June 17, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
May 26, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.